ArticleClinical and vaccine immunology : CVI2015
Proteins Selected in Leishmania (Viannia) braziliensis by an Immunoproteomic Approach with Potential Serodiagnosis Applications for Tegumentary Leishmaniasis.
Article in Clinical and vaccine immunology : CVI, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 3 syntheses or guidelines pooled it, 76 citations in OpenAlex.
- Global Landscape of Molecular and Immunological Diagnostic Tests for Human Leishmaniasis: A Systematic Review and Meta-Analysis.Pathogens (Basel, Switzerland) · 2025Pooled it
- Potential antigenic targets used in immunological tests for diagnosis of tegumentary leishmaniasis: A systematic review.PloS one · 2021Pooled it
- Diagnostic accuracy of Enzyme-Linked Immunosorbent Assays to detect anti-Leishmania antibodies in patients with American Tegumentary Leishmaniasis: a systematic review.Revista do Instituto de Medicina Tropical de Sao Paulo · 2019Pooled it
- Comparison of a recombinant endonuclease III protein and its synthetic peptides in ELISA for the diagnosis of tegumentary leishmaniasis using human serum and urine samples: A preliminary study.PLoS neglected tropical diseases · 2026Article
- Pilot study evaluating a newly developed nanoparticle-based lateral flow assay for the diagnosis of cutaneous leishmaniasis in Sri Lanka.Tropical medicine and health · 2026Article
- Leishmania pyruvate kinase and mitochondrial processing protease: Two novel vaccine candidates, selected via a seroproteomic approach, trigger a protective immune response against murine cutaneous leishmaniasis.Medical microbiology and immunology · 2025Article
- Exploring Bioinformatics Solutions for Improved Leishmaniasis Diagnostic Tools: A Review.Molecules (Basel, Switzerland) · 2024Review
- Accuracy of serological tests in diagnosing mucosal leishmaniasis.Parasitology research · 2023Article
- Immunoproteomics and phage display in the context of leishmaniasis complexity.Frontiers in immunology · 2023Review
- Development of an immunogen containing CD4Applied microbiology and biotechnology · 2022Article
- Validation of an In-House ELISA Method in the Diagnosis of Cutaneous Leishmaniasis Caused byMicroorganisms · 2022Article
- Identification of Immunodominant Antigens From a First-Generation Vaccine Against Cutaneous Leishmaniasis.Frontiers in immunology · 2022Article
- The use of filamentous hemagglutinin adhesin to detect immune responses toFrontiers in veterinary science · 2022Article
- Development of a chimeric protein based on a proteomic approach for the serological diagnosis of human tegumentary leishmaniasis.Applied microbiology and biotechnology · 2021Article
- Laboratory Diagnosis of Cutaneous and Visceral Leishmaniasis: Current and Future Methods.Microorganisms · 2020Review
- Evaluation of the protective efficacy of a Leishmania protein associated with distinct adjuvants against visceral leishmaniasis and in vitro immunogenicity in human cells.Parasitology research · 2020Article
- An immunoproteomics approach to identifyParasitology · 2020Article
- Article
- A candidate vaccine for human visceral leishmaniasis based on a specific T cell epitope-containing chimeric protein protects mice againstNPJ vaccines · 2020Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The serodiagnosis of human tegumentary leishmaniasis (TL) presents some problems, such as the low level of antileishmanial antibodies found in most of the patients, as well as the cross-reactivity in subjects infected by other trypanosomatids. In the present study, an immunoproteomic approach was performed aimed at identification of antigens in total extracts of stationary-phase promastigote and amastigote-like forms of Leishmania (Viannia) braziliensis using sera from TL patients. With the purpose of reducing the cross-reactivity of the identified proteins, spots recognized by sera from TL patients, as well as those recognized by antibodies present in sera from noninfected patients living in areas where TL is endemic and sera from Chagas disease patients, were discarded. Two Leishmania hypothetical proteins and 18 proteins with known functions were identified as antigenic. The study was extended with some of them to validate the results of the immunoscreening. The coding regions of five of the characterized antigens (enolase, tryparedoxin peroxidase, eukaryotic initiation factor 5a, β-tubulin, and one of the hypothetical proteins) were cloned in a prokaryotic expression vector, and the corresponding recombinant proteins were purified and evaluated for the serodiagnosis of TL. The antigens presented sensitivity and specificity values ranging from 95.4 to 100% and 82.5 to 100%, respectively. As a comparative antigen, a preparation of Leishmania extract showed sensitivity and specificity values of 65.1 and 57.5%, respectively. The present study has enabled the identification of proteins able to be employed for the serodiagnosis of TL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.